A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma

Leukemia and Lymphoma

Volumn 48, Issue 1, 2007, Pages 39-45

  Vose, Julie ^a   Panwalkar, Amit ^a   Belanger, Robert ^b   Coiffier, Bertrand ^c   Baccarani, Michele ^d   Gregory, Stephanie ^e   Facon, Thierry ^f   Fanin, Renato ^g   Caballero, Dolores ^h   Ben Yehuda, Dina ⁱ   Giles, Francis ^j  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c Centre Hospitalier Lyon   (France)

^d Policlinico sant'Orsola Malpighi   (Italy)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF UDINE   (Italy)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁱ HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TROXACITABINE; 1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; CYTOSINE; DRUG DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER DISEASE; BLOOD TOXICITY; BONE DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DERMATITIS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; EAR DISEASE; ESOPHAGUS DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; INFECTION; INFESTATION; INJECTION SITE REACTION; INNER EAR DISEASE; KIDNEY DISEASE; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MALE; MENTAL DISEASE; METABOLIC DISORDER; MUCOSAL DISEASE; MULTICENTER STUDY; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OPEN STUDY; OUTCOME ASSESSMENT; PETECHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; RELAPSE; RESPIRATORY TRACT DISEASE; SEPTIC SHOCK; SKIN DISEASE; TOXICITY TESTING; VASCULAR DISEASE; BIOLOGICAL MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; LEUKEMIA; LYMPHOMA; MIDDLE AGED; MORTALITY; PHASE 1 CLINICAL TRIAL; RECURRENT DISEASE; SALVAGE THERAPY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CYTOSINE; DIOXOLANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; RECURRENCE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34247211114     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600909578     Document Type: Article

References (23)

1. Vose, J. M., Anderson, J. R., Kessinger, A., Bierman, E. J., Coccia, P. and Reed, E. C. (1993) High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol, 11, pp. 1846-1151.
2. McLaughlin, P., Hagemeister, F. B., Romaguera, J. E., Sarris, A. H., Pate, O. and Younes, A. (1996) Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol, 14, pp. 1262-1268.
3. Johnson, P WM, Rohatiner, Z. S., Whelan, J. S., Price, C GA, Love, S. and Lim, J. (1995) Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol, 13, pp. 140-147.
4. Hass, R., Moos, M., Karcher, A., Mohle, R., Witt, B. and Goldschmidt, H. (1994) Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma. J Clin Oncol, 12, pp. 1685-1692.
5. Smith, M. L. and Newland, A. C. (1999) Treatment of myeloma. Q J Med, 92, pp. 11-14.
6. Balzarini, J., Wedgwood, O., Kruining, S., Pelemans, H., Heijtink, R. and De Clercq, E. (1996) Anti-HIV and anti-HBV activity and resistance profile of 2′,3′-dideoxy-3′-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. Biochem Biophys Res Commun, 225, pp. 363-369.
7. Mar, E. C., Chu, C. J. and Lin, J. C. (1995) Some nucleoside analogs with anti-human immunodeficiency virus activity inhibit replication of Epstein-Barr virus. Antiviral Res, 28, pp. 1-11.
8. Coates, J. A., Cammack, N., Jenkinson, H. J., Jowett, A. J., Mowett, M. I. and Pearson, B. A. (1992) (-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother, 36, pp. 733-739.
9. Mansour, T. S., Jin, H., Wang, W., Hooke, E. U., Ashman, C. and Cammack, N. (1995) Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2′-deoxy-3′-oxa-4′-thiocytidine and their 5-fluoro analogues in vitro. J Med Chem, 38, pp. 1-4.
10. Grove, K. L. and Cheng, Y. C. (1996) Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res, 56, pp. 4187-4191.
11. Grove, K. L., Guo, X., Liu, S. H., Gao, Z., Chu, C. K. and Chen, Y. C. (1995) Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res, 55, pp. 3008-3011.
12. Kadhim, S. A., Bowlin, T. L., Waud, W. R., Angers, E. G., Bibeau, L. and DeMuys, J. M. (1997) Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res, 57, pp. 4803-4810.
13. Siu, L. L., Attardo, G., Izbicka, E., Lawrence, R., Cerna, C. and Gomez, L. (1998) Activity of (-)-2′-deoxy-3′-oxacytidine (BCH-4556) against human tumor colony-forming units. Ann Oncol, 9, pp. 885-891.
14. Giles, F. J., Cortes, J. E., Baker, S. D., Thomas, D. A., O'Brien, S. and Smith, T. L. (2001) Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol, 19, pp. 762-771.
15. Oken, M. M., Creech, R. T., Tormey, D. C., Horton, J., Davis, T. E. and McFadden, E. T. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 5, pp. 649-655.
16. Cockcroft, D. W. and Gault, M. H. (1976) Prediction of creatinine clearance from serum creatinine. Nephron, 16, pp. 31-41.
17. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, V. A., Fisher, R. I. and Connors, J. M. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas NCI Sponsored International Working Group. J Clin Oncol, 17, p. 1244.
18. Cheson, B. D., Bennett, J. M., Rai, K. R., Grever, H. R., Kay, N. E. and Schiffer, C. a. (1988) Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored working group. Am J Hematol, 29, pp. 152-163.
19. Kaplan, E. and Meier, P. (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, pp. 457-481.
20. Kukhanova, M., Liu, S., Mozzherin, D., Lin, T., Chu, C. K. and Cheng, Y. (1995) L- and D-enantiomers of 2′,3′-dideoxycytidine 5′-triphosphate analogs as substrates for human DNA polymerases Implications for the mechanism of toxicity. J Biol Chem, 270, pp. 23055-23059.
21. Chou, K., Kukhanova, M. and Cheng, Y. (2000) A novel action of human apurinic/apyrimidinic endonuclease: Excision of L-configuration deoxyribonucleoside analogs from the 3′ termini of DNA. J Biol Chem, 275, pp. 31009-31015.
22. Gourdeau, H., Leblond, L., Hamelin, B., Dong, K., Quellet, F. and Boudreau, C. (2004) Species differences in troxacitabine pharmacokinetics and pharmacodynamics: Implications for clinical development. Clin Cancer Res, 10, pp. 7692-7702.
23. Giles, F. J., Faderl, S., Thomas, D. A., Cortes, J. B. and Garcia-Manero, G. (2003) Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol, 21, pp. 1050-1056.